BriefingIndustry newsIndustry briefingNEWSFDA grants priority review for Biogen’s tofersen to treat ALSThe US FDA has granted priority review for Biogen’s New Drug Application (NDA) for its gene therapy tofersen to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)newsAmgen to acquire biopharma firm ChemoCentryx for $3.7bnAmgen has signed a definitive agreement to acquire ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bnBriefingBeiGene reports Phase III tislelizumab data in hepatocellular cancerBeiGene reported positive data from the Phase III RATIONALE 301 trial of tislelizumab as a first-line therapy for adult unresectable HCC patientsIndustry newsIndustry briefing02/23/2024 22:05:12
Briefing
BeiGene reports Phase III tislelizumab data in hepatocellular cancer
BeiGene reported positive data from the Phase III RATIONALE 301 trial of tislelizumab as a first-line therapy for adult unresectable HCC patients